Proof of concept of intracochlear drug administration by laser-assisted bioprinting in mice.
Hearing Research. 2023-10-01; 438: 108880
DOI: 10.1016/j.heares.2023.108880
Read on PubMed
Jaffredo M(1), Duchamp O(2), Touya N(3), Bouleau Y(4), Dulon D(5), Devillard R(6), Bonnard D(7).
Author information:
(1)SATT Aquitaine, Aquitaine Science Transfert, Talence, France; INSERM UA06, Univ. Bordeaux, Bordeaux, France.
(2)CHU de Bordeaux, Bordeaux, France.
(3)INSERM U1026 BIOTIS, Univ. Bordeaux, Bordeaux, France.
(4)INSERM UA06, Univ. Bordeaux, Bordeaux, France.
(5)INSERM UA06, Univ. Bordeaux, Bordeaux, France; Institut de l’Audition, Centre Institut Pasteur/Inserm, Paris, France.
(6)CHU de Bordeaux, Bordeaux, France; INSERM U1026 BIOTIS, Univ. Bordeaux,
Bordeaux, France.
(7)CHU de Bordeaux, Bordeaux, France; INSERM UA06, Univ. Bordeaux, Bordeaux,
France. Electronic address: .
Transtympanic administration is used clinically for the injection of gentamicin
and/or corticosteroids. This atraumatic route is based on passive diffusion
through the round window membrane (RWM). The main limitation of this method is
related to the clearance through the Eustachian tube, making the concentration
of the therapeutic agent at the intracochlear level uncertain and limited.
Moreover, this technique remains unsuitable for molecules of high molecular
weight or in the case of gene therapies. The purpose was to study a new
technique of intracochlear administration in an atraumatic, direct and
controlled manner by laser-assisted bioprinting (LAB). LAB was used to deliver
dexamethasone phosphate with thermosensitive hydrogel on the mouse RWM. After
validation of the regularity and homogeneity of the pattern, the diffusion in
vivo of the dexamethasone into the perilymph after LAB has been confirmed by
ELISA. Auditory function measurements showed no hearing impairment suggesting
that bioprinting does not induce significant cochlear damage. Hence, the present
proof of concept study introduces a promising approach for inner ear drug
delivery.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement: Declaration of Competing Interest The authors have no conflict of interest to declare.